Evidence map›Paper›PMID 33050651›Full record

ArticleCancers2020

Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience.

Nidale Tarek, Rabih Said, Clark R Andersen, Tina S Suki, Jessica Foglesong, Cynthia E Herzog, Nizar M Tannir, Shreyaskumar Patel, Ravin Ratan, Joseph A Ludwig and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. The Diagnostic Quandary of Primary Renal Ewing's Sarcoma onWorld journal of nuclear medicine · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. [Experience in diagnosis and treatment of 6 cases of renal Ewing's sarcoma with venous thrombus].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. A rare radiotherapy-sensitive primitive neuroectodermal tumor withThe Journal of international medical research · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Nidale TarekDepartment of Pediatrics, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Rabih SaidDepartment of Investigational Cancer Therapeutics, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Clark R AndersenDepartment of Biostatistics, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Tina S SukiDepartment of Pediatrics, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jessica FoglesongDepartment of Pediatrics, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-1283-717X
Cynthia E HerzogDepartment of Pediatrics, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Nizar M TannirDepartment of Genitourinary Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Shreyaskumar PatelDepartment of Sarcoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ravin RatanDepartment of Sarcoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Joseph A LudwigDepartment of Sarcoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Najat C DawDepartment of Pediatrics, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-6941-8005
The University of Texas MD Anderson Cancer Center · USLurie Children's Hospital · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Limited information exists on the clinical behavior of the Ewing sarcoma family of tumors (ESFT) of the kidney. We reviewed the records of 30 patients (aged 8-69 years) with ESFT of the kidney seen at our institution between 1990 and 2013. We analyzed the event-free survival (EFS) and overall survival (OS) for associations with patient demographics, disease group, tumor size, tumor thrombus, and treatment. Six patients (20%) had tumors confined to the kidney (Group I), seven (23.3%) had local tumor extension beyond the kidney (Group II), and 17 (56.7%) had distant metastasis at diagnosis (Group III). Twenty-five (83.3%) patients underwent radical (19 upfront, five delayed) or partial (one upfront) nephrectomy, 25 (83.3%) chemotherapy and four (13.3%) radiotherapy. The 4-year EFS and OS were 43% (95% CI, 26-61%) and 63% (95% CI, 46-81%), respectively. EFS and OS were significantly associated with disease group and chemotherapy (

Indexed as

chemotherapyEwing sarcomakidneyoutcomerenalsurvivaltreatmenttumor thrombus

Identifiers

PMID33050651
PMCPMC7599660
OpenAlexW3092346079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.